ChromaVision and ACIS to be Featured At United States and Canadian Academy of Pathology Meeting.

Business Editors & Health/Medical Writers

SAN JUAN CAPISTRANO, Calif.--(BW HealthWire)--March 20, 2000

ChromaVision Medical Systems Inc. (Nasdaq:CVSN), a unique cellular imaging systems company and manufacturer of the Automated Cellular Imaging System (ACIS(TM)) Monday announced that scientific data related to automated imaging and the ACIS will be presented at educational sessions at the 89th Annual Meeting of United States and Canadian Academy of Pathology (USCAP) in New Orleans.

Featured speakers will be Kenneth D. Bauer, Ph.D., vice president and chief science officer of the company and Douglas S. Harrington, M.D., CEO and president of the company. The meeting will be held March 25 through March 31 at the New Orleans Hilton.

Five separate scientific abstracts report uniformly positive results when the ChromaVision ACIS was used to test for bone marrow occult metastasis, HER2 protein expression and cytomegalovirus antigenemia. The abstracts were accepted for formal presentation at USCAP and have been published in the January 2000 volume of the peer-reviewed medical journal Modern Pathology.

Authors of the ACIS-related abstracts include scientists and physicians from MD Anderson Cancer Center, University of Southern California School of Medicine, Emory University Medical School, independent pathology reference laboratories and ChromaVision. A hands-on ACIS demonstration will be available to USCAP attendees at ChromaVision's display booth in the meeting's technical exhibit hall.

About ChromaVision Medical Systems

ChromaVision Medical Systems has developed and markets a unique cellular imaging system designed to assist in the detection, diagnosis and treatment of cellular disease.

The Automated Cellular Imaging System (ACIS(TM)) combines proprietary, color-based imaging technology with automated microscopy to bring unprecedented sensitivity, accuracy and reproducibility to the assessment of cell-based diseases such as cancer and infectious disease.

ChromaVision currently markets its products to physicians and researchers in university medical centers and commercial laboratories throughout the world.

ChromaVision Medical Systems was formed by XL Vision Inc. and is a Safeguard Scientifics Inc. (NYSE:SFE) partnership company.

For more information on ChromaVision Medical Systems visit the company's Web site at http://www.chromavision.com.

The statements contained herein regarding ChromaVision Medical Systems Inc. contain forward-looking statements that involve risks and uncertainty. Future events and the company's actual results could differ materially from the results reflected in these forward-looking statements. Factors that might cause such a difference include, but are not limited to, uncertainty of success in developing any new diagnostic test, failure to obtain FDA clearance or approval for particular applications and dependence on third parties for clinical testing.

Note to Editors: ACIS is a trademark of ChromaVision Medical Systems Inc.